CD40 and neoplasm: As the aforementioned immunization experiments demonstrated that daily administration of GDC-0623 did not block the pro-immunogenic impact of agonist anti-CD40 Ab, we proceeded by testing the therapeutic efficacy of this Ab in combination with MEK inhibition in our tumor models.